• Profile
Close

Efficacy and safety of intravenous ceftriaxone at home vs intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): A single-centre, open-label, randomized, controlled, non-inferiority trial

The Lancet Infectious Diseases May 01, 2019

Ibrahim LF, et al. - In the Cellulitis at Home or Inpatient in Children from the Emergency Department (CHOICE) trial, intravenous antibiotic therapy at home was compared with standard treatment in hospital for children (aged 6 months to 18 years) with moderate to severe cellulitis regarding effectiveness and safety. Researchers randomly assigned children aged 6 months to 18 years who presented to the emergency department at The Royal Children's Hospital (Melbourne, VIC, Australia) with uncomplicated moderate to severe cellulitis to receive either intravenous ceftriaxone (50 mg/kg once daily; n=95) at home or intravenous flucloxacillin (50 mg/kg every 6 h; n=95) in hospital. Outcomes revealed non-inferiority of home treatment with intravenous ceftriaxone to treatment in hospital with intravenous flucloxacillin, which supports home or outpatient care as the standard of care for intravenous treatment of uncomplicated cellulitis in children, when feasible.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay